Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 4,239 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Study Product Clear all
Active, not recruiting Phase 3 Interventional

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

NCT04592913
View directory record Official record
Conditions
Gastrointestinal Neoplasms, Esophagogastric Junction
Interventions
Durvalumab, FLOT chemotherapy
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 200 Years
Enrollment
957 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Sylmar, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 31, 2026, 3:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Randomized, Placebo Controlled Trial of L Max in Healthy Adult Athletes

NCT07102680
View directory record Official record
Conditions
Healthy Normal Athletes
Interventions
L Max, Placebo
Other
Lead sponsor
Climatic, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 31, 2026, 3:19 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

NCT02362503
View directory record Official record
Conditions
HIV Infections
Interventions
BMS-663068, Placebo
Drug · Other
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
39
States / cities
Los Angeles, California • Palm Springs, California • San Francisco, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 31, 2026, 3:19 PM EDT
Not listed Not applicable Interventional

Impact of Adherence to Anemia Management Policy on Repeat Hospitalization in End Stage Renal Disease (ESRD)

NCT01017627
View directory record Official record
Conditions
Anemia, Mortality
Interventions
Early anemia diagnosis and treatment, No change from normal routine
Other
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
42
States / cities
Denver, Colorado • Jacksonville, Florida • Chicago, Illinois + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 31, 2026, 3:19 PM EDT
Completed Phase 3 Interventional Results available

Study of Postoperative Analgesia in Bunionectomy

NCT00890682
View directory record Official record
Conditions
Bunion, Hallux Valgus
Interventions
SKY0402, Placebo
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2013 · Synced Oct 31, 2026, 3:19 PM EDT
Completed Phase 3 Interventional

Multidisciplinary Approach to Reduce Injury and Substance Abuse

NCT01048359
View directory record Official record
Conditions
Drug Abuse
Interventions
Brief advice, Brief Intervention plus Booster, Brief Intervention
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 31, 2026, 3:19 PM EDT
Completed Phase 3 Interventional Results available

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

NCT03881696
View directory record Official record
Conditions
Peanut Allergy, Multi-food Allergy
Interventions
Omalizumab, Placebo for Omalizumab, Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen Oral Immunotherapy, Double-Blind Placebo-Controlled Food Challenge Based Treatment
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 55 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
10
States / cities
Little Rock, Arkansas • Stanford, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 31, 2026, 3:19 PM EDT
Terminated Phase 2 Interventional Results available

Effects of TAK-448 in Middle-aged and Older Men With Low Testosterone

NCT02381288
View directory record Official record
Conditions
Low Testosterone
Interventions
TAK-448, TAK-448 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
60 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 31, 2026, 3:19 PM EDT
Completed Not applicable Interventional

Post-market, Randomized, Controlled, Prospective Study Evaluating Intrathecal Pain Medication (IT) Versus Conventional Medical Management (CMM) in the Non-cancer, Refractory, Chronic Pain Population

NCT04096391
View directory record Official record
Conditions
Chronic Nonmalignant Pain, Pain, Intractable, Pain, Chronic
Interventions
Flowonix Prometra® II Programmable Infusion System, Pain Medicine
Device · Drug
Lead sponsor
Evolve Restorative Center
Other
Eligibility
22 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Santa Rosa, California
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 31, 2026, 3:19 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Use of Memantine In Combination With Anti-HIV Drugs to Treat AIDS Dementia Complex (ADC)

NCT00000867
View directory record Official record
Conditions
AIDS Dementia Complex, HIV Infections
Interventions
Memantine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Oct 31, 2026, 3:19 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Immediate Post-Operative Anesthesia With Either Lidocaine or Bupivacaine

NCT06293807
View directory record Official record
Conditions
Periodontal Diseases
Interventions
Xylocaine 2 % with 1:100,000 epinephrine, Bupivicaine 0.5% with 1:200,000 epinephrine, Placebo
Drug · Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Oct 31, 2026, 3:19 PM EDT
Completed Phase 1 Interventional

Effect of Stellate Ganglion Block on ME/CFS

NCT05664711
View directory record Official record
Conditions
Encephalomyelitis, Myalgic, Chronic Fatigue Syndrome, Chronic Fatigue Disorder, Chronic Fatigue and Immune Dysfunction Syndrome, Myalgic Encephalomyelitis, Postviral Fatigue Syndrome, Systemic Exertion Intolerance Disease, Infectious Mononucleosis-Like Syndrome, Chronic, Chronic Fatigue-Fibromyalgia Syndrome
Interventions
Bupivacaine Injection
Drug
Lead sponsor
Neuroversion, Inc.
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 31, 2026, 3:19 PM EDT
Completed Phase 2 Interventional Results available

Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)

NCT06011798
View directory record Official record
Conditions
Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus, Diabetic Retinopathy, Retinal Degeneration, Retinal Diseases, Eye Diseases, Edema
Interventions
Aflibercept, foselutoclax
Drug
Lead sponsor
Unity Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Bakersfield, California • Beverly Hills, California • Huntington Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 31, 2026, 3:19 PM EDT
Terminated Phase 2 Interventional

Cariprazine Effects on Brain and Behavior in Cocaine Use Disorder

NCT03430544
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Cariprazine Oral Capsule [Vraylar], Placebo oral capsule
Drug
Lead sponsor
Anna Rose Childress, Ph.D.
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 31, 2026, 3:19 PM EDT
Completed Phase 2 Interventional

A Study of Viracept in HIV-Positive Women

NCT00002171
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
13 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Birmingham, Alabama • Los Angeles, California • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 31, 2026, 3:19 PM EDT
Terminated Phase 1 Interventional

Next Generation Personalized Neuroblastoma Therapy

NCT02780128
View directory record Official record
Conditions
Neuroblastoma, Cancer
Interventions
Biopsy, Next Generation Sequencing, Tumor Scans, Bone marrow Tests, Physical Exam, Eye Exam, Labs, Pregnancy Test, Interviews, ECG, Echocardiogram, Ribociclib, Ceritinib
Procedure · Genetic · Other + 2 more
Lead sponsor
Yael P Mosse
Other
Eligibility
1 Year to 21 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 31, 2026, 3:19 PM EDT
Terminated Phase 3 Interventional Results available

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

NCT04729387
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Alpelisib, Olaparib, Paclitaxel, Pegylated liposomal doxorubicin (PLD)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
16
States / cities
Phoenix, Arizona • Fort Myers, Florida • West Palm Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 31, 2026, 3:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Efficacy of Botulinum Toxin B (Myobloc) for the Treatment of Prosthesis-associated Sweating

NCT01671800
View directory record Official record
Conditions
Hyperhidrosis
Interventions
Botulinum Type B, Placebo
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 31, 2026, 3:19 PM EDT
Completed Phase 2 Interventional

Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus

NCT02434744
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
KD026, Placebo, Metformin
Drug
Lead sponsor
Response Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • West Hills, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 31, 2026, 3:19 PM EDT
Completed Phase 3 Interventional Results available

Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl

NCT01081132
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Extended-release Guanfacine Hydrochloride, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
54
States / cities
Dothan, Alabama • Little Rock, Arkansas • Rolling Hills Estates, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 31, 2026, 3:19 PM EDT
Completed Phase 1 Interventional Results available

A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder

NCT04447287
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
ASP8062, Placebo ASP8062, buprenorphine/naloxone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 31, 2026, 3:19 PM EDT
Completed Not applicable Interventional Results available

Trauma Survivors Outcomes and Support Study IV

NCT01625416
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Depression, Suicide, Traumatic Brain Injury, Alcohol Use, Drug Use
Interventions
Stepped Care Management
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
14 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 31, 2026, 3:19 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics

NCT00951899
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Colesevelam, Placebo, Diet, Metformin
Drug · Other · Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 31, 2026, 3:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Sleep Disruption on Drug Response

NCT03680287
View directory record Official record
Conditions
Low Back Pain, Recurrent, Healthy
Interventions
Within-Subject test of blinded study medication
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 31, 2026, 3:19 PM EDT